# Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.

> **NCT02887677** · PHASE4 · TERMINATED · sponsor: **Hellenic Society for Medical Education** · enrollment: 85 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02887677
- **Lead sponsor:** Hellenic Society for Medical Education
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2019-06
- **Final completion:** 2019-10
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02887677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02887677, "Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02887677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*